Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Intravenous Immunoglobulin Market Heading Into 2029?
There has been a significant growth in the intravenous immunoglobulin market over the recent years. It is predicted to inflate from $14.66 billion in 2024 to $15.57 billion in 2025 with a compound annual growth rate (CAGR) of 6.2%. The growth during the historical period can be credited to the treatment of primary immunodeficiency disorders, handling of neurological disorders, increase in elderly population, advancement in plasma fractionation techniques, expanded indications in neurology, treatment of infectious diseases, and pediatric immunodeficiency treatment.
It is anticipated that the intravenous immunoglobulin market will experience robust expansion in the upcoming years. It is projected to inflate to “$21.53 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. The various factors contributing to the growth during the forecast period include a surge in autoimmune disorders, continuous exploration in immunology, escalating healthcare expenses, an increase in cancer rates, progress in immunoglobulin products, and tailored medical treatments. Key developments predicted in the forecast period comprise treatment for primary immunodeficiency disorders (PIDD), swift technological advancements, strategic alliances and partnerships, improvements in production processes, usages in neurology and hematology, and progress in immunotherapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp
Which Factors Are Pushing The Intravenous Immunoglobulin Market Forward?
The surge in the aging population is projected to propel the intravenous immunoglobulin market. Essentially, the geriatric demographic represents individuals who are more than 65 years old. Immunity tends to decline with age and there’s a shortage of antibodies. Hence, this older age group requires immunoglobulins for supplementing their antibodies. This necessity increases the demand for intravenous immunoglobulins, thus advancing the intravenous immunoglobulin market. For instance, future projections from the Population Reference Bureau, a non-profit organization in Kenya, suggest that by January 2024, the American population aged 65 and above would rise from 58 million in 2022 to 82 million by 2050, marking a 47% growth. The same reports predict a rise in this age group’s share in the total population from 17% to 23%. Consequently, the growing geriatric population is set to stimulate the expansion of the intravenous immunoglobulin market.
Which Segment Held The Largest Share In The Intravenous Immunoglobulin Market In 2025?
The intravenous immunoglobulin market covered in this report is segmented –
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care
Subsegments:
1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG
2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM
3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA
4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE
5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD
What Are The Leading Trends And Opportunities In The Intravenous Immunoglobulin Sector?
The intravenous immunoglobulin market is seeing an uptick in product innovation, as top companies strive to develop new products and consolidate their market position. Notably, treatments for immunodeficiency diseases, such as liquid immune globulin formulations, are at the forefront of this innovation. For example, in December 2023, GC Pharma, a company based in South Korea, introduced Alyglo, a product endorsed by the US Food and Drug Administration (FDA). This ready-to-use, sterile liquid formulation comprises 10% immunoglobulin G (IgG), which includes at least 96% human IgG derived from pooled human plasma – thus delivering 100mg/ml protein. The formulation is intended for adults aged 17 years and older suffering from primary humoral immunodeficiency (PI), as well as diseases such as congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, severe combined immunodeficiency (SCID).
Which Organizations Are Driving Progress In The Intravenous Immunoglobulin Industry?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Which Region Is Expected To Experience The Highest Growth In The Intravenous Immunoglobulin Industry?
North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model